Association of intravenous administration of human Muse cells with deficit amelioration in a rat model of spinal cord injury - PubMed
- ️Fri Jan 01 2021
. 2021 Jan 1;34(4):648-655.
doi: 10.3171/2020.7.SPINE20293. Print 2021 Apr 1.
Affiliations
- PMID: 33385996
- DOI: 10.3171/2020.7.SPINE20293
Association of intravenous administration of human Muse cells with deficit amelioration in a rat model of spinal cord injury
Takumi Kajitani et al. J Neurosurg Spine. 2021.
Abstract
Objective: Multilineage-differentiating stress-enduring (Muse) cells are pluripotent stem cells, which can be harvested from the bone marrow. After transplantation, Muse cells can migrate to an injured site of the body and exert repair effects. However, it remains unknown whether Muse cell transplantation can be an effective treatment in spinal cord injury (SCI).
Methods: The authors used a rat model of thoracic spinal cord contusion injury. For Muse cell transplantation, the clinical product CL2020 containing 300,000 Muse cells was administered intravenously 1 day after midthoracic SCI. Animals were divided into CL2020 (n = 11) and vehicle-treated (n = 15) groups. Behavioral and histological evaluations were conducted over a period of 8 weeks to see whether intravenous CL2020 administration provided therapeutic effects for SCI. The effects of human-selective diphtheria toxin on reversion of the therapeutic effects of CL2020 were also investigated.
Results: Hindlimb motor function significantly improved after CL2020 transplantations. Importantly, the effects were reverted by the human-selective diphtheria toxin. In immunohistochemical analyses, the cystic cavity formed after the injury was smaller in the CL2020 group. Furthermore, higher numbers of descending 5-hydroxytryptamine (5-HT) fibers were preserved distal to the injury site after CL2020 administration. Eight weeks after the injury, Muse cells in CL2020 were confirmed to differentiate most predominantly into neuronal cells in the injured spinal cord.
Conclusions: Following SCI, Muse cells in CL2020 can reach the injured spinal cord after intravenous administration and differentiate into neuronal cells. Muse cells in CL2020 facilitated nerve fiber preservation and exerted therapeutic potential for severe SCI.
Keywords: Muse cell; cell transplantation; intravenous administration; rat; spinal cord injury.
Similar articles
-
Takahashi Y, Kajitani T, Endo T, Nakayashiki A, Inoue T, Niizuma K, Tominaga T. Takahashi Y, et al. Int J Mol Sci. 2023 Sep 27;24(19):14603. doi: 10.3390/ijms241914603. Int J Mol Sci. 2023. PMID: 37834052 Free PMC article.
-
Multilineage Differentiating Stress Enduring (Muse) Cells: A New Era of Stem Cell-Based Therapy.
Alanazi RF, Alhwity BS, Almahlawi RM, Alatawi BD, Albalawi SA, Albalawi RA, Albalawi AA, Abdel-Maksoud MS, Elsherbiny N. Alanazi RF, et al. Cells. 2023 Jun 21;12(13):1676. doi: 10.3390/cells12131676. Cells. 2023. PMID: 37443710 Free PMC article. Review.
-
Koda M, Imagama S, Nakashima H, Ito S, Segi N, Ouchida J, Suda K, Harmon Matsumoto S, Komatsu M, Endo T, Suzuki S, Inami S, Ueda H, Miyagi M, Inoue G, Takaso M, Nagata K, Yamada H, Kamei N, Nakamae T, Suzuki H, Nishida N, Funaba M, Kumagai G, Furuya T, Yamato Y, Funayama T, Takahashi H, Yamazaki M. Koda M, et al. Stem Cell Res Ther. 2024 Aug 13;15(1):259. doi: 10.1186/s13287-024-03842-w. Stem Cell Res Ther. 2024. PMID: 39135172 Free PMC article. Clinical Trial.
-
Nagaoki T, Kumagai G, Nitobe Y, Sasaki A, Fujita T, Fukutoku T, Saruta K, Tsukuda M, Asari T, Wada K, Dezawa M, Ishibashi Y. Nagaoki T, et al. J Neurotrauma. 2023 Dec;40(23-24):2596-2609. doi: 10.1089/neu.2022.0470. Epub 2023 May 16. J Neurotrauma. 2023. PMID: 37051701
-
Kuroda Y, Oguma Y, Hall K, Dezawa M. Kuroda Y, et al. Front Pharmacol. 2022 Oct 19;13:1027961. doi: 10.3389/fphar.2022.1027961. eCollection 2022. Front Pharmacol. 2022. PMID: 36339573 Free PMC article. Review.
Cited by
-
Takahashi Y, Kajitani T, Endo T, Nakayashiki A, Inoue T, Niizuma K, Tominaga T. Takahashi Y, et al. Int J Mol Sci. 2023 Sep 27;24(19):14603. doi: 10.3390/ijms241914603. Int J Mol Sci. 2023. PMID: 37834052 Free PMC article.
-
Furuta A, Kuroda Y, Yamamoto T, Egawa S, Dezawa M, Yoshimura N. Furuta A, et al. Int Urogynecol J. 2022 May;33(5):1293-1301. doi: 10.1007/s00192-022-05166-w. Epub 2022 Mar 25. Int Urogynecol J. 2022. PMID: 35333929
-
Cell Therapy for Neurological Disorders: The Perspective of Promising Cells.
Liu D, Bobrovskaya L, Zhou XF. Liu D, et al. Biology (Basel). 2021 Nov 6;10(11):1142. doi: 10.3390/biology10111142. Biology (Basel). 2021. PMID: 34827135 Free PMC article. Review.
-
Multilineage Differentiating Stress Enduring (Muse) Cells: A New Era of Stem Cell-Based Therapy.
Alanazi RF, Alhwity BS, Almahlawi RM, Alatawi BD, Albalawi SA, Albalawi RA, Albalawi AA, Abdel-Maksoud MS, Elsherbiny N. Alanazi RF, et al. Cells. 2023 Jun 21;12(13):1676. doi: 10.3390/cells12131676. Cells. 2023. PMID: 37443710 Free PMC article. Review.
-
Kato Y, Aburakawa D, Tashiro R, Zhou Y, Rashad S, Endo H, Tominaga T, Niizuma K. Kato Y, et al. J Cereb Blood Flow Metab. 2024 Oct 13:271678X241290363. doi: 10.1177/0271678X241290363. Online ahead of print. J Cereb Blood Flow Metab. 2024. PMID: 39397400 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical